Literature DB >> 241655

Pharmacology of nadolol (SQ 11725), a beta-adrenergic antagonist lacking direct myocardial depression.

R J Lee, D B Evans, S H Baky, R J Laffan.   

Abstract

SQ 11725 was approximately 1/3 as potent as propranolol in blocking the stimulant effects of isoproterenol in vitro, but was 2-4 times more potent than propranolol in blocking the diastolic blood-pressure and heart-rate responses, respectively, to isoproterenol in vivo. SQ 11725 had no depressant effects on contractile force of isolated guinea pig atrial muscle at the largest bath concentration studied (1000 mug/ml), whereas propranolol caused significant depression at a concentration of 1-10 mug/ml. Propranolol was at least 20-30 times more depressant than SQ 11725 to canine myocardium in vivo. SQ 11725 was more effective then propranolol in inhibiting tachycardic responses to treadmill exercise in unanesthetized dogs. The duration of blockade of the heart-rate response to exercise or to isoproterenol administration in the unanesthetized dog was approximately 5 times greater with SQ 11725 than with propranolol.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 241655     DOI: 10.1016/0014-2999(75)90182-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  23 in total

1.  Agonist and antagonist characterization of a putative adrenoceptor with distinct pharmacological properties from the alpha- and beta-subtypes.

Authors:  R A Bond; D E Clarke
Journal:  Br J Pharmacol       Date:  1988-11       Impact factor: 8.739

2.  Effect of propranolol on ventricular repolarization and refractoriness: role of beta-blockade versus direct membrane effects.

Authors:  D E Euler; P J Scanlon
Journal:  Cardiovasc Drugs Ther       Date:  1988-03       Impact factor: 3.727

3.  Comparative effect of nadolol and propranolol on exercise tolerance in patients with angina pectoris.

Authors:  G G Turner; R R Nelson; L A Nordstrom; H C Diefenthal; F L Gobel
Journal:  Br Heart J       Date:  1978-12

4.  Antihypertensive action of beta-adrenoceptor blockade and the renin-angiotensin system.

Authors:  I Gavras; H Gavras; H R Brunner; C S Liang
Journal:  Br J Clin Pharmacol       Date:  1979       Impact factor: 4.335

5.  Concentration-effect relationships with FM 24: a new long acting beta-adrenergic receptor antagonist.

Authors:  C T Dollery; H J Dargie; J Sassard; G Cuisinaud
Journal:  Br J Clin Pharmacol       Date:  1983-06       Impact factor: 4.335

6.  A study of nadolol to determine its effect on ambulatory blood pressure over 24 hours, and during exercise testing.

Authors:  R S Hornung; B A Gould; H Kieso; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1982-07       Impact factor: 4.335

7.  Interactions of beta-adrenoceptor antagonists and thyroid hormones in the control of heart rate in the dog.

Authors:  M C Allely; A Ungar
Journal:  Br J Pharmacol       Date:  1985-10       Impact factor: 8.739

8.  Comparison between atenolol and nadolol in essential hypertension at rest and on exercise.

Authors:  R G Wilcox; J R Hampton
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

9.  Comparison of antianginal efficacy of one conventional and three long acting beta-adrenoreceptor blocking agents in stable angina pectoris.

Authors:  G R Jones; M A Mir
Journal:  Br Heart J       Date:  1981-11

10.  Characterization of propranolol-resistant (-)-[125I]-cyanopindolol binding sites in rat soleus muscle.

Authors:  S J Roberts; P Molenaar; R J Summers
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.